Maintenance with rituximab is not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIB MAXIMA study

被引：0
|
作者：
Witzens-Harig, M. [1 ]
Di Rocco, A. [2 ]
van Hazel, G. [3 ]
Chamone, D. [4 ]
Ruffert, K.
Rowe, J. [5 ]
Arcaini, L. [6 ]
Poddubnaya, I. [7 ]
Ho, A. [1 ]
Ivanova, V. [8 ]
Vranowsky, A. [9 ]
Oertel, S. [10 ]
Thurley, D. [11 ]
Foa, R. [2 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
[2] Sapienza Univ, Rome, Italy
[3] Mt Hosp, Perth, WA, Australia
[4] FMUSP, Hosp Clin, Sao Paulo, Brazil
[5] Technion Israel Inst Technol, Haifa, Israel
[6] Univ Pavia, I-27100 Pavia, Italy
[7] Blokhin Canc Res Ctr, Moscow, Russia
[8] Botkin Municipal Clin Hosp, Moscow, Russia
[9] Natl Oncol Inst, Bratislava, Slovakia
[10] F Hoffman La Roche Ltd, Basel, Switzerland
[11] Roche Prod Pty Ltd, Dee Why, Australia
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [21] Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma (vol 5, pg 118, 2023)
    Li, Ru
    Wang, Tingyu
    Lyv, Rui
    Wang, Yi
    Yu, Ying
    Yan, Yuting
    Sun, Qi
    Xiong, Wenjie
    Liu, Wei
    Sui, Weiwei
    Huang, Wenyang
    Wang, Huijun
    Li, Chengwen
    Wang, Jun
    Zou, Dehui
    An, Gang
    Wang, Jianxiang
    Qiu, Lugui
    Yi, Shuhua
    BLOOD SCIENCE, 2023, 5 (03): : 219 - 219
  • [22] Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Esseltine, Dixie-Lee
    Neuwirth, Rachel
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (06) : 920 - 928
  • [23] Enzastaurin in patients with follicular lymphoma: Results of a phase II study
    Schwartzberg, L.
    Hermann, R. C.
    Flinn, I. W.
    Flora, D. B.
    Song, J.
    Hamid, O.
    Lin, B. K.
    Dreyling, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] The MAXIMA study:: Safety of rituximab (MabThera®) maintenance therapy in patients with follicular non-Hodgkin's lymphoma who have responded to induction therapy
    Wenger, Michael K.
    Foa, Robin
    Arcaini, Luca
    Vranovsky, Andrej
    Ivanova, Valentina
    Guy, Van Hazel
    Kurtovic, Sabira
    Duran, Soledad
    McKechnie, Stephen
    Thurley, Daniel
    BLOOD, 2007, 110 (11) : 189B - 190B
  • [25] PHARMACOECONOMIC EVALUATION OF RITUXIMAB AS MAINTENANCE TREATMENT FOR FOLLICULAR LYMPHOMA: RESULTS OF A REAL WORLD POPULATION BASED STUDY
    Blommestein, H.
    Issa, D.
    Pompen, M.
    Huijgens, P.
    Revil, C.
    Uyl-de Groot, C.
    HAEMATOLOGICA, 2012, 97 : 329 - 329
  • [26] Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Revil, Cedric
    Hoogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    BLOOD, 2012, 120 (21)
  • [27] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
    Sehn, Laurie H.
    Luminari, Stefano
    Scholz, Christian W.
    Huebel, Kai
    Salar, Antonio
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Panayiotidis, Panayiotis
    Lee, Hui-Peng
    Ubieto, Ana Jimenez
    Sancho, Juan-Manuel
    Kim, Tae Min
    Domenech, Eva Domingo
    Kumode, Takahiro
    Poh, Christina
    Thieblemont, Catherine
    Deeren, Dries
    de Wit, Edwin
    Arbushites, Michael
    Casadebaig, Marie-Laure
    Trneny, Marek
    BLOOD, 2024, 144 : LBA1 - LBA4
  • [28] MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
    Andorsky, David J.
    Yacoub, Abdulraheem
    Bitran, Jacob D.
    Melear, Jason
    Brooks, Heather D.
    Foon, Kenneth A.
    Rizvi, Syed
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff P.
    BLOOD, 2016, 128 (22)
  • [29] Rituximab activity is potentiated by GM-CSF in patients with relapsed, follicular lymphoma:: Results of a phase II study.
    Rossi, JF
    Lu, ZY
    Quittet, P
    Baudard, M
    Rouillé, V
    Klein, B
    BLOOD, 2005, 106 (11) : 684A - 684A
  • [30] Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
    Czuczman, Myron S.
    Fayad, Luis
    Delwail, Vincent
    Cartron, Guillaume
    Jacobsen, Eric
    Kuliczkowski, Kazimierz
    Link, Brian K.
    Pinter-Brown, Lauren
    Radford, John
    Hellmann, Andrzej
    Gallop-Evans, Eve
    DiRienzo, Christine G.
    Goldstein, Nancy
    Gupta, Ira
    Jewell, Roxanne C.
    Lin, Thomas S.
    Lisby, Steen
    Schultz, Martin
    Russell, Charlotte A.
    Hagenbeek, Anton
    BLOOD, 2012, 119 (16) : 3698 - 3704
12345